Showing results (851-860 of 3,789) with videos related to

Sort By:
Pageof 379
Oncoimmunology|December 21, 2023
g-NK cells from umbilical cord blood are phenotypically and functionally different than g-NK cells from peripheral bloodFei Gao, Mauricio Campos Mora, Michael Constantinides, et al.
Oncoimmunology|December 21, 2023
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patientsSandra García-Mulero, Roberto Fornelino, Marco Punta, et al.
Oncoimmunology|February 12, 2024
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibitionYikun Li, Peiliang Wang, Junhao Xu, et al.
Oncoimmunology|February 12, 2024
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancerPatrik Sundström, Nikita Dutta, William Rodin, et al.
Oncoimmunology|January 18, 2024
An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomesLeqian Ying, Zhangmin Hu, Yi Lu, et al.
Oncoimmunology|January 23, 2024
Immunoseroproteomic profiling in autoantibody to ENO1 as potential biomarker in immunodiagnosis of osteosarcoma by serological proteome analysis (SERPA) approachJitian Li, Liping Dai, Manyu Huang, et al.
Oncoimmunology|January 29, 2024
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapyKevin Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke, et al.
Oncoimmunology|March 15, 2024
Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progressionMargot Revel, Mikel Rezola Artero, Houcine Hamidi, et al.
Oncoimmunology|March 22, 2024
Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinomaMin Ma, Liang Li, Shu-Han Yang, et al.
Oncoimmunology|March 22, 2024
Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistanceReshmi Nair, Tamsin R M Lannagan, Rene Jackstadt, et al.
Pageof 379